Pfizer compresses as J&J expands ops structure

Pfizer's new CEO Ian Read has flattened the drug giant's org chart, eliminating the global head level. Unit heads will report to him instead, to speed decision-making. Tony Maddaluna will take over global manufacturing early next year when Nat Ricciardi retires. Meanwhile, J&J head Bill Weldon has added a layer at the board level. Sheri McCoy, currently global chairman for the pharma division, will become a vice chairman for the executive committee. She's being groomed as a potential successor to Weldon and will sit atop the manufacturing and quality-control overhaul at McNeil. Article | Story

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.